Decoy Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring on February 24, 2026, regarding Decoy Therapeutics Inc. (DCOY). The filing details the results of a virtual special meeting of stockholders held to vote on three specific corporate proposals.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
Stockholders approved all three proposals presented at the special meeting. A total of 2,696,758 shares were present and entitled to vote, constituting a quorum.
- Proposal 1 (Equity Incentive Plan): Approved. Votes For: 351,837; Votes Against: 68,978; Abstentions: 55,703.
- Proposal 2 (Reverse Stock Split): Approved. The amendment authorizes a reverse split of outstanding common stock at a ratio between 1-for-4 and 1-for-15, to be determined by the Board of Directors. Votes For: 2,187,125; Votes Against: 507,474; Abstentions: 2,173.
- Proposal 3 (Adjournment): Approved but deemed unnecessary. Votes For: 2,237,338; Votes Against: 450,908; Abstentions: 8,526. Adjournment was not required as Proposals 1 and 2 received sufficient support.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation that the proposals were approved by the requisite majority. The filing notes that the reverse stock split ratio will be finalized at the discretion of the Board of Directors within the authorized range. No specific risks, contingencies, or forward-looking guidance regarding financial performance are disclosed in this document.
Key Facts for Investor Verification
- Verify the specific reverse stock split ratio (1-for-4 to 1-for-15) once determined by the Board of Directors.
- Confirm the effective date of the reverse stock split and the corresponding adjustment to the trading symbol or price on the Nasdaq Capital Market.
- Review the definitive proxy statement filed on January 9, 2026, for detailed terms of the 2026 Equity Incentive Plan.
- Monitor subsequent filings for the implementation of the stock split and any impact on share count and liquidity.